Safety and efficacy of pulse and daily calcitriol in patients on CAPD: a randomized trial.

What Was Tested

The paper reports a study of Vitamin D and Calcitriol, published as a randomized controlled trial.

Calcitriol therapy is the mainstay of therapy for the treatment of secondary hyperparathyroidism.

Oral administration of calcitriol is necessary in CAPD patients, but no studies have directly compared different routes of administration in this patient population.

Who Took Part

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

The patients were dialysed with low-calcium dialysate and received only calcium-containing phosphate binders.

How the Study Was Run

The design is described as randomized.

The participants were allocated by chance, so the Vitamin D group and the comparison group should start out alike.

The main comparison was the rate of decline of serum intact parathyroid hormone (PTH) levels to reach the desired end-point of 100 pg/ml.

What Was Measured

Calcitriol therapy is the mainstay of therapy for the treatment of secondary hyperparathyroidism.

Topics PubMed links to this paper include Calcitriol, Calcium, Hyperparathyroidism, Osmolar Concentration, Parathyroid Hormone, Peritoneal Dialysis, Continuous Ambulatory and Vitamin D.

What This Means in Plain Language

The paper is a randomized study of Vitamin D and Calcitriol.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 1998 (Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association), a journal based in England.

More context: the related Vitamin D, K2, Magnesium and Zinc library page, all human trials.